IHE:NYE-iShares U.S. Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 63.49

Change

-0.29 (-0.45)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-22 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.03 (-0.78%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-0.44 (-0.71%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-0.82 (-0.81%)

USD 0.90B
XHE SPDR® S&P Health Care Equipme..

-0.37 (-0.46%)

USD 0.16B
IDNA iShares Genomics Immunology an..

+0.18 (+0.89%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-1.98 (-2.02%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

-0.03 (-0.12%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.01 (-0.03%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-0.07 (-0.12%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.14 (+0.76%)

USD 0.01B

ETFs Containing IHE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.39% 81% B- 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.39% 81% B- 36% F
Trailing 12 Months  
Capital Gain -3.42% 67% D+ 34% F
Dividend Return 0.99% 88% B+ 21% F
Total Return -2.43% 71% C- 29% F
Trailing 5 Years  
Capital Gain 23.97% 71% C- 46% F
Dividend Return 8.86% 95% A 20% F
Total Return 32.83% 71% C- 38% F
Average Annual (5 Year Horizon)  
Capital Gain 2.70% 67% D+ 48% F
Dividend Return 4.08% 67% D+ 44% F
Total Return 1.38% 100% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 14.23% 62% D 66% D+
Risk Adjusted Return 28.68% 67% D+ 46% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike